Early in the COVID-19 pandemic, New Zealand had as little as five days of RT-qPCR reagent supply on hand to service its testing needs. The country sits at the end of most global supply lines, separated from its nearest neighbours by ocean rather than a land border.

Jo-Ann Stanton led a team of New Zealand scientists who asked a deliberately uncomfortable question: in a genuine worst-case scenario, where international reagent supply became completely unavailable, could New Zealand manufacture everything needed for a COVID-19 RT-qPCR test onshore, from raw chemical precursors.

The answer was yes. The team synthesised their own reverse transcriptase and thermostable polymerase from bacterial cultures, built their own dNTPs and labelled probes from base chemical stock, and purified their own RNase inhibitor from sheep liver. The resulting assay, named HomeBrew RT-qPCR, performed comparably to a commercial diagnostic test across fourteen clinical samples.

It is a genuinely different kind of paper for us to share, not a story about our extraction chemistry, but about the same scientific leadership behind it, applied to a much bigger question: what happens to a small, isolated country's diagnostic capacity when the rest of the world is also in crisis.